Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants | Ocugen, Inc.

▤ Summary

Ocugen announced a registered direct offering of common stock and warrants to raise about $20 million before fees and expenses. Janus Henderson Investors agreed to buy 20 million shares and warrants for up to another 20 million shares at $1.00 per share. The warrants are immediately exercisable, expire in two years, and could add up to $30 million more if fully exercised. The offering is expected to close around August 11, 2025, subject to customary conditions. Ocugen says it develops gene therapies for blindness diseases and will use the financing to support its biotechnology business.

$ Funding

▦ Linked Companies